CSL Limited (CMXHF)
OTCMKTS · Delayed Price · Currency is USD
130.00
-0.67 (-0.52%)
Oct 9, 2025, 11:07 AM EDT
CSL Limited Employees
CSL Limited had 29,904 employees as of June 30, 2025. The number of employees decreased by 2,794 or -8.54% compared to the previous year.
Employees
29,904
Change (1Y)
-2,794
Growth (1Y)
-8.54%
Revenue / Employee
$520,265
Profits / Employee
$100,388
Market Cap
65.57B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 29,904 | -2,794 | -8.54% |
| Jun 30, 2024 | 32,698 | 633 | 1.97% |
| Jun 30, 2023 | 32,065 | 2,065 | 6.88% |
| Jun 30, 2022 | 30,000 | 5,000 | 20.00% |
| Jun 30, 2021 | 25,000 | -2,000 | -7.41% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
| Jushi Holdings | 1,234 |
| Nuo Therapeutics | 9 |
CSL Limited News
- 3 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 3 days ago - CSL Behring Canada Signs LOI With PCPA For Public Reimbursement Of HEMGENIX - Nasdaq
- 7 weeks ago - CSL Limited falls as layoffs overshadow FY25 results - Seeking Alpha
- 7 weeks ago - CSL Limited (CSLLY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Full Year 2025 CSL Ltd Earnings Presentation Transcript - GuruFocus
- 7 weeks ago - CSL Limited 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 7 weeks ago - Australian biopharma firm CSL posts 14% rise in annual profit - Reuters
- 4 months ago - U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start - PRNewsWire